{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BI+655130", "query": { "intervention": "BI 655130" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T13:54:07.961Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05013385", "title": "A Study to Test Whether Spesolimab Helps People With Crohn's Disease Who Have Symptoms of Bowel Obstruction", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibrostenotic Crohn´s Disease" ], "interventions": [ { "name": "Spesolimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 5, "start_date": "2021-11-09", "completion_date": "2022-05-31", "has_results": true, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-09-04T13:54:07.961Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05013385" }, { "nct_id": "NCT04015518", "title": "A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Palmoplantar Pustulosis (PPP)" ], "interventions": [ { "name": "Spesolimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 152, "start_date": "2019-07-31", "completion_date": "2021-07-28", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-04T13:54:07.961Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Beverly Hills, California • San Diego, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04015518" }, { "nct_id": "NCT03782792", "title": "Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Generalized Pustular Psoriasis" ], "interventions": [ { "name": "Spesolimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 53, "start_date": "2019-01-31", "completion_date": "2021-01-05", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-04T13:54:07.961Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Miami, Florida • Tampa, Florida + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03782792" }, { "nct_id": "NCT05856526", "title": "A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Netherton Syndrome" ], "interventions": [ { "name": "Spesolimab - solution for infusion", "type": "DRUG" }, { "name": "Placebo matching to spesolimab - solution for infusion", "type": "DRUG" }, { "name": "Spesolimab - solution for injection", "type": "DRUG" }, { "name": "Placebo matching to spesolimab - solution for injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 43, "start_date": "2023-06-12", "completion_date": "2025-07-31", "has_results": true, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-09-04T13:54:07.961Z", "location_count": 4, "location_summary": "Rancho Santa Margarita, California • New Haven, Connecticut • Charleston, South Carolina + 1 more", "locations": [ { "city": "Rancho Santa Margarita", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05856526" }, { "nct_id": "NCT06624670", "title": "A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pyoderma Gangrenosum" ], "interventions": [ { "name": "Spesolimab", "type": "DRUG" }, { "name": "Placebo matching to spesolimab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2025-02-05", "completion_date": "2028-08-19", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-04T13:54:07.961Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06624670" }, { "nct_id": "NCT03482635", "title": "BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Spesolimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 98, "start_date": "2018-03-27", "completion_date": "2020-05-18", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-04T13:54:07.961Z", "location_count": 13, "location_summary": "Hamden, Connecticut • Miami, Florida • Orlando, Florida + 10 more", "locations": [ { "city": "Hamden", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03482635" }, { "nct_id": "NCT04399837", "title": "A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Generalized Pustular Psoriasis" ], "interventions": [ { "name": "Spesolimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 123, "start_date": "2020-06-04", "completion_date": "2022-11-23", "has_results": true, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-09-04T13:54:07.961Z", "location_count": 2, "location_summary": "Auburn Hills, Michigan • St Louis, Missouri", "locations": [ { "city": "Auburn Hills", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04399837" }, { "nct_id": "NCT03822832", "title": "A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "BI 655130", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 51, "start_date": "2019-02-12", "completion_date": "2020-07-22", "has_results": true, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-09-04T13:54:07.961Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03822832" }, { "nct_id": "NCT03648541", "title": "BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Spesolimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2018-10-29", "completion_date": "2023-05-03", "has_results": true, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-09-04T13:54:07.961Z", "location_count": 8, "location_summary": "Hamden, Connecticut • Atlanta, Georgia • Chicago, Illinois + 5 more", "locations": [ { "city": "Hamden", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03648541" }, { "nct_id": "NCT04086121", "title": "A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "Spesolimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 14, "start_date": "2019-09-24", "completion_date": "2022-02-23", "has_results": true, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-09-04T13:54:07.961Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Plainfield", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04086121" } ] }